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A B S T R A C T
Evaluation of tumoral programmed cell death ligand-1 (PD-L1) expression is standard practice for patients with
advanced non-small-cell lung cancer (NSCLC) who may be candidates for treatment targeting the programmed
cell death-1 (PD-1)/PD-L1 pathway. Currently, all of the commercially available immunohistochemistry assays
have been validated for use with histology specimens although, in routine clinical practice, approximately
30–40 % of patients with advanced NSCLC have only cytology specimens available for diagnosis, staging, and
biomarker analysis. This systematic review evaluated the success rate, concordance, and clinical utility of using
cytology specimens to assess tumor PD-L1 expression levels compared with histology specimens from patients
with advanced NSCLC. EMBASE and PubMed database searches identified 142 unique, relevant publications, of
which 15 met the inclusion criteria for at least one analysis. In 709 specimens, across seven publications, the
proportion of cytology specimens evaluable for PD-L1 testing was 92.0 %. Among nine studies eligible for
concordance analysis between cytology and histology specimens at a PD-L1 tumor cell expression cutoff of
≥50 %, overall percentage agreement was 89.7 % (n = 428), 72.0 % for positive percentage agreement
(n = 218), and 95.0 % for negative percentage agreement (n = 258); results using a tumor PD-L1 expression
cutoff of ≥1 % were similar. Our analyses suggest that using cytology specimens to assess PD-L1 expression is
feasible, with good levels of concordance between cytology and histology specimens using PD-L1 tumor cell
expression cutoffs of ≥1 % and ≥50 %. In conclusion, there is no convincing evidence that cytology specimens
are inadequate or inferior to histology specimens for assessing PD-L1 expression in patients with NSCLC.
1. Introduction
Antibodies targeting the programmed cell death-1 (PD-1)/
programmed cell death ligand-1 (PD-L1) pathway have improved out-
comes for patients with advanced non-small-cell lung cancer (NSCLC),
and are now approved in several countries [1–7]. As improved clinical
outcomes with these antibodies are often associated with higher
tumor PD-L1 expression levels in NSCLC [1,3,7,8], different
PD-L1 QJ/>expression cutoffs have been investigated in clinical trials
and as part of the co-development of immunohistochemistry (IHC) assays.
This has led to a number of approvals which restrict the use of
PD-(L)1-targeting antibodies to patients whose tumors express PD-L1
above prespecified thresholds. For example, pembrolizumab is approved
by both the United States Food and Drug Administration and the Eur-
opean Medicines Agency for the first-line treatment of patients with
metastatic NSCLC whose tumors have high PD-L1 expression (tumor
proportion score ≥50 %) and no EGFRmutations or ALK rearrangements,
with a recent extension in the United States and Japan to all patients
whose tumors express PD-L1 (tumor proportion score ≥1 %) [3,8–11].
Alongside molecular testing for genomic aberrations, PD-L1 testing is
therefore mandated or recommended to help guide treatment decisions
[12,13].
The validity of testing for PD-L1 expression in cytology specimens,
which are characterized by the dispersed nature of the tumor cells (TCs)
within them, represents a practical problem for pathologists and on-
cologists. To reiterate, only histology specimens, in which TCs are
maintained within their structural and architectural context, were used
in clinical trials of antibodies targeting the PD-1/PD-L1 pathway and
during the co-development of IHC-based assays. As a result, a range of
IHC assays for PD-L1 testing are now approved and commercially
available as either companion or complementary diagnostics. These
include the VENTANA PD-L1 (SP142) Assay [14]; the VENTANA PD-L1
(SP263) Assay [15]; the PD-L1 IHC 22C3 pharmDx assay [16]; and the
PD-L1 IHC 28-8 pharmDx assay [17].
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Cytology specimens are therefore not formally validated as a sub-
strate for the assessment of PD-L1 expression using IHC assays.
However, approximately 30–40 % of patients with advanced NSCLC
have only cytology specimens available for diagnosis and analysis of
predictive or prognostic biomarkers [18,19]. These cytology specimens
include smears or cell blocks obtained from pleural or pericardial ef-
fusions or by fine-needle aspiration (FNA) of the primary tumor or its
metastases, including endoscopic bronchial ultrasound (EBUS)-guided
aspirates of intrathoracic lymph nodes. FNAs are not only less invasive
than tissue biopsies, but facilitate sampling multiple zones within the
same tumor and its metastases during a single procedure [20]. Fur-
thermore, there is an additional rationale to evaluate this approach for
PD-L1 assessment as current guidelines already accept the use of cy-
tology specimens for detecting EGFR mutations and ALK or ROS1 gene
rearrangements [21]. With EBUS-guided aspiration of intrathoracic
lymph nodes now the preferred approach in most thoracic oncology
centers for the diagnosis, staging, and profiling of NSCLC [22], exclu-
sion of such specimens from PD-L1 testing will potentially deny many
patients appropriate and effective treatment. Understanding the feasi-
bility and validity of using cytology specimens for assessing PD-L1
expression in patients with NSCLC is therefore highly pertinent.
Here, we report the results of a systematic review of PD-L1 testing in
cytology specimens from patients with advanced NSCLC. We evaluated
the success rate of using cytology specimens to assess PD-L1 expression
levels and concordance with histology specimens, and reviewed any
available data comparing efficacy in patients who had PD-L1 expression
assessed using cytology or histology specimens.
2. Methods
We searched the EMBASE and PubMed databases (search date
February 11–12, 2019) using the terms ‘PD-L1 and NSCLC and
(cytolog* OR FNA OR fine-needle aspirate OR cell smear OR cell block
OR endobronchial ultrasound [EBUS] OR transbronchial needle as-
piration [TBNA])’ present in any field. The asterisk (*) serves as a
truncation symbol. Additional references were identified using biblio-
graphies. Abstracts and papers were manually reviewed for relevance.
Articles that were not written in English and studies that did not report
PD-L1 assessed by IHC were excluded.
For the analysis of success rate of PD-L1 testing, specimens had to
have ≥100 TCs. Success was defined as the proportion of submitted
specimens that was evaluable for PD-L1 testing. For the concordance
analysis, prespecified inclusion criteria were: negative, overall, and
positive percentage agreement (NPA, OPA, and PPA, respectively) re-
ported or that were derivable from raw data; analysis of paired
(matched patient) cytology and histology specimens; reported cutoff for
PD-L1 TC expression (defined as the percentage of TCs with any
membranous PD-L1 expression); and NSCLC. Data from studies using
either cell blocks or smears were included in the concordance analysis.
Where data from both were presented within the same paper, results
from cell blocks were used. Both success rate and concordance analyses
used only studies reported in peer-reviewed journals. However, the
review of clinical efficacy data included abstracts due to limited data
availability. If multiple abstracts or manuscripts referred to the same
dataset, the most recent manuscript was used, or the most recent ab-
stract where only abstracts were available.
For the concordance analysis, upper and lower 95 % confidence
intervals (CIs) were calculated using the Clopper‒Pearson method [23].
3. Results
Our searches of the EMBASE and PubMed databases identified a
total of 141 unique publications and abstracts, with one additional
publication identified through bibliography searches (Fig. 1). In total,
13 peer-reviewed publications were included in at least one analysis.
Seven peer-reviewed publications were included in the analysis of
success rate, and nine were included in the concordance analysis; one
manuscript and two abstracts reporting clinical efficacy data were also
identified. Due to the scarcity of data and the small sample numbers
analyzed in these publications, efficacy data are described in the Dis-
cussion section.
3.1. Success rate analysis
Based on 709 specimens tested across seven studies reported in
peer-reviewed publications [24–30], the success rate for PD-L1 testing
Fig. 1. Flow diagram of study inclusion.
*Publications which met inclusion for success rate, concordance or efficacy analysis; publications may have been included in more than one analysis.
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using cytology specimens was 92.0 % (Table 1). This was consistent
with the success rate based on data published additionally in
13 abstracts (93.2 %; N = 1331; data not shown).
3.2. Concordance analysis
Nine studies were eligible for analysis of concordance between
matched cytology and histology specimens with PD-L1 expression data
based on staining on TCs (Tables 2 and 3) [24,25,28,31–36]. Across the
nine studies identified, the OPA for cytology and histology specimens
(n = 428) was 88.3 % (95 % CI: 86.9–91.2) and 89.7 % (95 % CI:
86.5–92.4) for specimens with ≥1 % and ≥50 % of TCs expressing PD-
L1, respectively. The PPA for cytology and histology specimens with
≥1 % of TCs expressing PD-L1 (n = 218) was 78.0 % (95 % CI:
Table 1
Successa rate of PD-L1 testing using cytology specimensb from patients with NSCLC in eligible publications identified by systematic review.
Reference Sample type Fixation method Antibody clone N Success rate (%)
Capizzi et al. (2018) [24] Smear MicroFix spray (Diapath SpA, Italy) Ventana SP263 50 98
Noll et al. (2018) [25] Smear Not specified 22C3 pharmDx 41 90
Cell block Formalin fixation 22C3 pharmDx 41 93
Wang et al. (2018) [26] Cell block Cytolyt (Hologic Inc., Marlborough, MA, USA) or alcohol,
followed by 10 % NBF; 10 % NBF alone; TissuFix (Chaptec
Inc, Montreal, Canada); or Cytolyt or 50 % alcohol alonec
22C3 pharmDx 371 92
Torous et al. (2018) [27] Cell block Formalin fixationd 22C3 pharmDx 94 94
Heymann et al. (2017) [28] Cell block NBF or Cytolyt 22C3 pharmDx 40 90
Biswas et al. (2018) [29] Cell block Alcohol fixation 22C3 pharmDx 50 86
Stoy et al. (2018) [30] Cell block Not specified Abcam 28.8 22 91
NBF, neutral-buffered formalin; TC, tumor cell.
a Success defined as the proportion of submitted specimens that were evaluable for PD-L1 testing.
b All cytology specimens used to determine the success rate had ≥100 TCs.
c The fixation method was known for 261 (76 %) cytology specimens.
d Specimens were collected into Cytolyt fixative solution, before further formalin fixation.
Table 2
Concordance in PD-L1 staining levels between matched histology and cytology specimensa from patients with NSCLC in eligible studies identified by systematic
review.
Reference Antibody clone Sample collection N PD-L1 cutoffb OPA PPA NPA
Arriola et al. (2018) [31] 22C3 pharmDx Core needle biopsy 15 TC ≥ 1 %







Hernandez et al. (2019) [32] 22C3 pharmDx FNA, pleural effusion or bronchial
brushes
52 TC ≥ 1 %







Heymann et al. (2017) [28] 22C3 pharmDx EBUS-FNA, FNA, thoracentesis or
pericardiocentesis
4 TC ≥ 1 %







Ilie et al. (2018) [33] 22C3 (laboratory developed test) Pleural effusion or bronchial washes 70 TC ≥ 1 %







Noll et al. (2018) [25] 22C3 pharmDx EBUS-FNA, ultrasound-guided FNA, or
CT-guided FNA
38 TC ≥ 1 %







Sakata et al. (2018) [34] 22C3 pharmDx EBUS-TBNA 61 TC ≥ 1 %







Skov et al. (2017) [35] 22C3 pharmDx CT-guided FNA, FNA, EBUS-/
EUS-FNA, or pleural effusion
86 TC ≥ 1 %







Capizzi et al. (2018) c [24] Ventana SP263 FNA 49 TC ≥ 1 %







Munari et al. (2019) c [36] Ventana SP263 FNA 53 TC ≥ 1 %







CT, computed tomography; EBUS-FNA, endobronchial ultrasound-guided fine-needle aspiration; EBUS-TBNA, endobronchial ultrasound-guided transbronchial
needle aspiration; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; FNA, fine-needle aspiration; N/A, not applicable or calculable (no negative his-
tology specimens based on the TC≥1 % cutoff level); NPA, negative percentage agreement; OPA, overall percentage agreement; PPA, positive percentage agreement;
TC, tumor cell; TPS, tumor proportion score.
a All data presented were based on analysis of cell blocks, except as indicated.
b PD-L1 expression level based on proportion of TC staining or TPS.
c Comparison based on cytological smear.
Table 3
Overall concordance in PD-L1 staining levels between matched cytology and
histology specimens across nine studies identified by systematic review.
PD-L1 expression cutoff
n PD-L1 TC ≥ 1 % n PD-L1 TC ≥ 50 %
OPA, % (95 % CI) 428 88.3 (86.9–91.2) 428 89.7 (86.5–92.4)
PPA,a % (95 % CI) 218 78.0 (71.9–83.3) 100 72.0 (62.1–80.5)
NPA,a % (95 % CI) 140 89.3 (82.9–93.9) 258 95.0 (91.5–97.3)
CI, confidence interval; NPA, negative percentage agreement; OPA, overall
percentage agreement; PD-L1, programmed cell death ligand-1; PPA, positive
percentage agreement; TC, tumor cell.
a NPA and PPA data only derivable for a subset of publications.
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71.9–83.3) and 72.0 % (95 % CI: 62.1–80.5) for specimens with
≥50 % of TCs expressing PD-L1 (n = 100), while the NPA was 89.3 %
(95 % CI: 82.9–93.9) and 95.0 % (95 % CI: 91.5–97.3) for specimens
with ≥1 % of TCs expressing PD-L1 (n = 140) and ≥50 % of TCs
expressing PD-L1 (n = 258), respectively.
4. Discussion
To date, evaluation of tumoral PD-L1 expression as a predictive
biomarker for response to immune checkpoint blockade in patients with
NSCLC has been informed by the assessment of histology specimens
with most data coming from pivotal, registration-directed trials.
However, the reality is that, in many centers, cytology specimens are
frequently used to evaluate PD-L1 expression levels and to inform
treatment decisions for many patients with advanced NSCLC. A better
understanding of the validity of using this sampling approach for PD-L1
analysis is therefore of considerable clinical relevance.
To our knowledge, this is the first systematic review comparing PD-
L1 testing using cytology and histology specimens. Our analyses suggest
that use of cytology specimens to assess PD-L1 expression is feasible,
with over 90 % of PD-L1 tests using cytology specimens yielding an
interpretable result. Additionally, we found good levels of concordance
between cytology and histology specimens that had PD-L1 expression
on ≥1 % or ≥50 % of TCs, with an OPA of 88.3 % and 89.7 %, re-
spectively. Based on our results, which suggest high levels of OPA and
NPA between cytology and histology specimens for scoring PD-L1 ex-
pression, false positive results are expected to be rare when using cy-
tology specimens. However, because the PPA was lower than the OPA
and NPA between cytology and histology specimens across both PD-L1
cutoffs, there is a risk that PD-L1 expression in cytology specimens
might be underestimated in some cases. Despite this, these analyses
support the use of cytology specimens for the current clinically relevant
PD-L1 expression cutoffs, including the approvals for pembrolizumab in
the first-line setting based on ≥1 % and ≥50 % cutoffs [3,8–11], and
the approval of durvalumab in the European Union for patients with
locally advanced, unresectable NSCLC who have not progressed fol-
lowing platinum-based chemoradiotherapy and whose tumors express
PD-L1 (PD-L1 TC ≥ 1 %) [37].
Our systematic literature search identified three retrospective
studies that compared clinical efficacy in patients with advanced
NSCLC using either cytology or histology specimens to assess PD-L1
expression. In one study, 232 consecutive patients were assessed for
PD-L1 expression levels; the majority of patients had advanced NSCLC
and 81 patients had tumors with ≥50 % of TCs expressing PD-L1. Of
these, 20 patients received first-line treatment with pembrolizumab
(11 based on testing using cytology specimens and 9 based on histology
specimens) and 19 were evaluable for efficacy analysis. The objective
response rate was 20 % in the cytology group and 22 % in the histology
group (p = 1.0). The disease control rate (DCR) at 6 weeks was 60 %
and 56 % for the cytology and histology groups, respectively (p = 1.0)
[27]. In another study, 65 patients with advanced NSCLC were treated
with immunotherapy targeting the PD-1/PD-L1 pathway; 50 (77 %)
patients received pembrolizumab, 10 (15 %) patients received nivo-
lumab, and 5 (8 %) patients received other immunotherapies in ran-
domized clinical trials. Twenty (31 %) patients were treated in the first-
line setting, 36 (55 %) patients in the second-line setting, and the re-
maining patients were treated in the third-line setting. Thirty-eight of
the 65 patients had tumors that expressed PD-L1 on ≥50 % of TCs and
were available for efficacy analysis according to the type of specimen
used for PD-L1 IHC staining. In these patients, there was no statistically
significant difference between patients assessed for PD-L1 expression
using cytology (n = 13; DCR 69 %) or small biopsy specimens (n = 25;
DCR 68 %; p = 0.93) [38]. A third study compared clinical outcomes in
patients seen by a medical oncologist for consideration of systemic
therapy, including immune checkpoint blockade, between March 2014
and June 2017, and whose tumors had PD-L1 expression on ≥50 % of
TCs based on either cytology or histology specimens. There was no
difference in median overall survival between patients assessed using
cytology (n = 32; 11.9 months) or histology specimens (n = 37; 8.0
months), irrespective of treatment received (adjusted hazard ratio 0.98;
95 % CI: 0.43–2.26). Of note, patients in the cytology group received
more systemic treatment than the histology group (p = 0.009), while
the histology group received more palliative radiotherapy (p = 0.044)
[39]. Although the identified clinical data were limited by very small
patient numbers, were of a retrospective nature and, in one publication
identified, the compared patient groups received different amounts of
systemic treatment and palliative radiotherapy, the results from these
studies suggest that patients whose tumors have PD-L1 expression on
≥50 % of TCs assessed using cytology specimens may have similar
clinical outcomes to those in whom it was assessed using histology
specimens. However, these findings need to be confirmed in pro-
spective, appropriately designed trials.
There are several inherent challenges associated with assessing
PD-L1 expression levels in cytology compared with histology speci-
mens. It is clear, for example, that the dispersion of cells in cytology
compared with histology specimens may make scoring PD-L1 expres-
sion particularly challenging at low expression levels and when applied
to a cutoff of ≥1 % of TCs expressing PD-L1. Additionally, due to the
fact that cell membranes in cell smears or cytospins are intact rather
than cut, membranous expression of PD-L1 is less clear than in cell
blocks or tissue sections [40]. These challenges may explain the ob-
servation that PPA was lower than the achieved values for OPA and
NPA in our analysis. Most of the cytology PD-L1 expression data have,
however, been derived from assessment of stained cut-sections from cell
block preparations, an approach more likely to recapitulate the findings
in a tissue biopsy sample.
There are also inherent challenges associated with the handling of
cytology compared with histology specimens, including the use of
fixatives. Compared with histology specimens, a much wider range
of fixatives is used for cytology specimens and, in the case of cells
blocks, there is also variability in the preservative solutions used before
formalin fixation and paraffin embedding [40]. Additionally, it has
been suggested that both the antigenicity and expression levels of
PD-L1 might be affected by using alcohol-based fixatives, rather than
neutral-buffered formalin as routinely used for histology specimens
[18]. However, in one study, PD-L1 expression did not differ either
qualitatively or quantitatively between cytology specimens fixed in
formalin or alcohol [26]. Similarly, in a recent study comparing 50
matched pairs of EBUS-guided aspirates taken from the same tumor
deposit or lymph node during the same procedure, there was no sig-
nificant difference, qualitatively or quantitatively, between specimens
fixed in either alcohol or formalin in terms of the pattern or extent of
PD-L1 expression [41]. In addition, there was no difference according
to whether the alcohol-fixed specimens were or were not post-fixed in
formalin.
A minimum of 100 cells is generally accepted as a necessity to en-
sure reliable interpretation of PD-L1 expression using IHC [19,42]. Our
analysis of the success rate of cytology specimens to assess PD-L1 ex-
pression was restricted to studies that specified that the specimens as-
sessed had ≥100 % TCs. Across the nine studies included in the con-
cordance analysis, six specified that specimens had to have ≥100 TCs
and the remaining three studies had a majority of specimens with ≥100
TCs. Interestingly, in one study, agreement between PD-L1 testing of
cytology specimens with fewer than 100 cells and the corresponding
histology specimens was much lower than the agreement observed
based on cytology specimens with ≥100 cells [32]. Another study,
however, which included bronchial washings and cells from pleural
effusions [33], described good concordance irrespective of the number
of TCs in the specimen. However, in a further study, a minimum of 100
TCs was required in a single biopsy specimen to assess PD-L1 expression
to predict responses to treatment with nivolumab in patients with non-
squamous NSCLC [43].
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The importance of assessing the reliability of cytology specimens for
PD-L1 assessment across commercially available assays has been re-
cognized by the Blueprint PD-L1 IHC Comparability Project [44]. In this
study, 24 expert pulmonary pathologists from 15 different countries
scored a set of 22 cytology specimens. Moderately good agreement was
observed between pathologists for the scoring of TCs across five com-
mercially available IHC assays (intraclass correlation coefficient [ICC]
0.78 and 0.85 for glass slide and digital readings, respectively), al-
though the agreement was lower than that observed in histology spe-
cimens (ICC 0.89 and 0.93 for glass slide and digital readings, respec-
tively). A further analysis from this study evaluated the concordance
between FNAs, core biopsies, and large sections from the same resected
tumor, and reaffirmed the comparability of cytology and histology
specimens for the assessment of PD-L1 expression by IHC [45]. How-
ever, pathologists rated a greater proportion of specimens from FNA
cell blocks compared with tissue biopsies as ‘unevaluable’ for de-
termining PD-L1 expression level. A separate, prospective, observa-
tional study comparing PD-L1 expression in cytology and histology
specimens from 184 patients with NSCLC of any stage (NCT03092739)
has recently been completed, although data have yet to be published
[46].
Limitations of our systematic review include the use of different
assays for assessing PD-L1 expression in the studies reviewed.
Additionally, none of the studies included in our review involved the
assessment of PD-L1 expression on immune cells, which are likely to be
more challenging to measure in cytology specimens. For example, re-
liable assessment of PD-L1 expression by immune cells cannot be made
using aspirates of lymph nodes, because such cells might not be integral
to the tumor. Various types of cytology specimen were analyzed and
there was wide variation in sample handling as well as likely variability
in the expertise of pathologists scoring the specimens. Some of the
studies had only small sample numbers, particularly those comparing
clinical outcomes based on specimen type used to evaluate PD-L1 ex-
pression.
The use of cytology specimens for assessing PD-L1 expression levels
via IHC assays is rapidly becoming accepted clinical practice. Given the
prevalence of patients who have only cytology specimens available for
diagnosis, staging, and biomarker analysis, it is a real-world necessity
that these specimens are used for the assessment of PD-L1 expression.
Pragmatism is required, however, when considering the use of practices
not formally validated in clinical trials to ensure that patients are not
denied effective treatment. The exclusion of cytology specimens from
clinical trials is unfortunate but, to some extent, understandable. Most
of these trials incorporate supplementary studies for extensive transla-
tional biomarker research, although the variability of cytology
specimens and the lack of adequate, usable tumor content in many of
them would lead to their exclusion. Furthermore, companies devel-
oping PD-L1 biomarker assays will usually not have access to cytology
specimens for assay validation. Consequently, validation of the prac-
tical approaches required in real-world clinical diagnostics is left to the
clinical community. Comprehensive and robust data are essential to
give this community confidence in using cytology specimens for PD-L1
testing and to reduce the use of more invasive procedures.
The available evidence from the studies identified and analyzed in
this systematic review suggests that cytology specimens are an
adequate substrate for assessing PD-L1 expression in patients with
advanced NSCLC, with no convincing evidence that they are inferior to
histology specimens. That said, there are two caveats: that assessment
must be confined to TCs and that a minimum of 100 TCs must be
available in the specimen for analysis. It might also be prudent to
standardize across laboratories the procedures used in preparing
cytology specimens for IHC, particularly with regard to routinely
post-fixing in formalin specimens already fixed in alcohol. Until further
evidence is provided, 10 % neutral buffered formalin should be
considered the gold-standard fixative. Additionally, data summarized in
this review support the use of cytology specimens for assessing PD-L1
expression at current clinically relevant cutoffs. Furthermore, although
there will always be some inherent variability in the proficiency and
experience among pathologists, there is nothing to suggest that
cytology specimens cannot be used with confidence. Despite the degree
of variation in pre-analytical factors and sample preparation with cy-
tology specimens, compared with the relatively standard procedures
used for histology specimens, we fully expect that experience in the use
of cytology specimens will undoubtedly build knowledge and expertise
in the different aspects of their assessment. As with all aspects of
clinical practice, the evidence must be robust in order to provide
confidence in utilizing a particular approach. In this instance, we may
need to adopt a more pragmatic approach to assess the utility of
cytology specimens which, for the reasons previously outlined, may not
achieve validation through the usual clinical trial process.
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